Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Entera Bio Ltd. - Ordinary Shares (NQ:ENTX)

3.150 +0.100 (+3.28%)
Delayed Quote Updated: 1:35 PM EST, Nov 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press Releases about Entera Bio Ltd. - Ordinary Shares

News headline image
Entera Appoints Global Research and Development Leader Dr. Juan Camilo Arjona Ferreira to Its Board of Directors
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Presents Markedly Enhanced Anabolic Effects of EB613 (First-in-Class Oral PTH(1-34) Tablet) in Postmenopausal Women with Osteoporosis at High Risk of Fracture and Showcases Phase 3 Design at ASBMR 2026 Annual Meeting
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Announces Additional Presentation of EB613 Phase 3 Study Design at the ASBMR 2026 Annual Meeting
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Appoints Global BioPharma Executive Laura Hamill to Its Board of Directors, Expanding Commercial Expertise
Former Gilead and Amgen executive joins Entera with over 35 years of experience advancing and commercializing impactful and blockbuster therapies 
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Correction: Entera to Participate in Upcoming Fall Investor Conferences
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera to Participate in Upcoming Fall Investor Conferences
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Appoints Global Pharmaceutical Leader Riccardo Paolo Camisasca, M.D., as Chief Medical Officer Ahead of Planned EB613 Phase 3 Initiation
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Announces Second Quarter 2026 Financial Results and Business Updates
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Phase 2 Data Supporting EB613’s (Oral PTH(1-34)) Anabolic Effect on Postmenopausal Women with Osteoporosis at High Risk for Fracture Selected for Plenary Poster Session Presentation at the ASBMR 2026 Annual Meeting
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio to Participate in the Canaccord Genuity 46th Annual Growth Conference
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Announces Pricing of Oversubscribed $275 Million Private Placement
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Receives Positive FDA Feedback on 12-Month Registrational Phase 3 Study for EB613 - the First Oral Anabolic Tablet in Development for Postmenopausal Women with Osteoporosis
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Reports Robust Preclinical Data for EB612 (Oral LA-PTH(1-34)) for Hypoparathyroidism and EB618 (Oral GLP-1/Glucagon) for Obesity at ENDO 2026
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
ENDO 2026 Oral Presentation Highlights Comparative Clinical Data for Entera’s Breakthrough Single Tablet EB613 (First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis)
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera’s EB613, First-in-Class Oral PTH(1-34) Anabolic for Osteoporosis - Single Tablet Data Selected for Late Breaking Oral Presentation at ENDO 2026 Annual Meeting; Additional Oral Peptide Pipeline Data Accepted for Presentation
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Announces First Quarter 2026 Financial Results and Updates Across its Oral Peptide Programs
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio to Host Key Opinion Leader Webinar Highlighting the Osteoporosis Treatment Landscape and the Opportunity for EB613
From Entera Bio Ltd.
Via GlobeNewswire
News headline image
Entera Bio Announces Pricing of $10.0 Million Direct Investment by BVF Partners with Potential for up to $24.5 Million in Total Proceeds
From Entera Bio Ltd.
Via GlobeNewswire
Big Pharma Just Put Peptides Back on the Map – Which Players Are Still Under the Radar?
Via AB Newswire
Could Oral Osteoporosis Treatment Become the Next GLP-1-Style Blockbuster?
Via AB Newswire
News headline image
Market Brief: After Viking Therapeutics’ Results, Is Entera Bio the Oral Platform Play to Watch? (NASDAQ: ENTX)
Via AB Newswire
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.